Lifecore Biomedical (LFCR) Proxy filing summary

Executive summary

• The 2024 annual meeting will be held virtually on November 7, 2024, with voting on director elections, auditor ratification, and executive compensation proposals.

• Only stockholders of record as of October 4, 2024, may vote, with separate proxy cards for Common Stock and Series A Preferred Stock holders.

• The board recommends voting for all director nominees, the ratification of BDO USA, P.C. as auditor, and approval of executive compensation.

• The company completed its first full year as a standalone CDMO, reporting $128.3 million in revenue, a 24.2% increase over the prior year.

• Fiscal 2024 included a CEO transition and strategic investments in production capacity and liquidity.

Voting matters and shareholder proposals

• Five directors are up for election: four by all stockholders and one Series A Preferred Director by Series A holders only.

• Proposals include ratifying BDO USA, P.C. as auditor and a non-binding advisory vote on executive compensation.

• Shareholder proposals for the 2025 meeting must be received by June 6, 2025, to be included in the proxy statement.

Board of directors and corporate governance

• The board will reduce from eleven to nine members at the annual meeting.

• Majority of directors are independent; the board includes a non-executive chairperson.

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all with independent members.

• Board diversity matrix discloses gender and demographic backgrounds per Nasdaq rules.

• Recent cooperation agreements led to new independent director appointments and nomination commitments through 2025.